- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04219046
Evaluation of Naloxegol in the Prevention of POI After Cystectomy (ANTAGOCYST)
Evaluation of Naloxegol, a Peripherally Acting µ-opioid Receptor Antagonist, in the Prevention of Postoperative Ileus After Cystectomy
Postoperative ileus (POI) is defined as a transient reduction of bowel motility that prevents effective transit of bowel content and tolerance of oral intake following surgical interventions, especially after radical cystectomy. It remains a major factor associated with postoperative morbidity, length of hospital stay and medical costs.
In order to optimize perioperative care for patients undergoing radical cystectomy in a context of an ERAS (Enhanced Recovery After Surgery) program, we will evaluate the effectiveness of systemic pharmacologic opioid antagonist treatment.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Radical cystectomy (RC) with urinary diversion represents the gold standard treatment for muscle-invasive bladder cancer. Postoperative ileus (POI) is defined as a transient reduction of bowel motility that prevents effective transit of bowel content and tolerance of oral intake following surgical interventions, especially after RC. It remains a major factor associated with postoperative morbidity, length of hospital stay and medical costs.
Faster gastrointestinal recovery and prevention of POI are at the heart of ERAS (Enhanced Recovery After Surgery) protocols. In order to optimize the post-operative consequences of patients operated on for a cystectomy within the framework of a RAAC program, several provisions aim to alleviate post-operative gastrointestinal dysfunctions.
Naloxegol, peripherally acting µ-opioid receptor antagonist, is currently approved for opioid-induced constipation in Chronic Non-Cancer Pain, but its potential interest to prevent POI has never been assessed. In this randomized, double-blind, placebo-controlled trial, the administration of Naloxegol for a limited duration as part of ERAS (Enhanced Recovery After Surgery) program will be evaluated to reduce the time of hospital discharge (length of stay) and to reduce the rate of postoperative complications. Priamry and secondary objectives will be compared between naloxegol and placebo groups.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Carine Cormary-Feuillet, PhD
- Phone Number: 33 4 91 22 58 82
- Email: drci.up@ipc.unicancer.fr
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients aged ≥ 18 years
- Informed consent signed
- Histopathological confirmation of bladder cancer
- Patients undergoing radical cystectomy and urinary diversion for an oncological indication
- Patients able to understand the study procedures, agreed to participate in the study program
- Patients affiliated to the national "Social Security" regimen or beneficiary of this regimen
Exclusion Criteria:
- Unwilling to undergo cystectomy
- Cystectomy for non-oncological indication
- Patients with concomitant upper urinary tract disease
- Previous total colectomy, gastrectomy, or gastric bypass, or functional colostomy or ileostomy
- Previous pelvic radiotherapy for prostate or bladder cancer
- Patients having taken opioids for more than seven days before surgery (to prevent peripheral withdrawal effects)
- Patients treated with drugs metabolized by certain enzymes (CYP3A4 and P-gp)
- Patients with severe hepatic impairment
- Patients with end-stage renal disease
- Patients with heart failure
- Patients with severe dementia that impacts daily functioning
- Pregnant and lactating females
- Not postmenopausal females and of childbearing potential and not using an accepted method of birth control (i.e, surgical sterilization; intrauterine contraceptive device; oral contraceptive, diaphragm)
- Patients participated in another investigational drug or medical device study within 30 days of surgery or planning to be enrolled in another investigational drug or medical device study or any study in which active patient participation was required outside normal hospital data collection during the course of this study
- Patients deprived of liberty or placed under the authority of a tutor or curator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Experimental Treatment
ERAS program with administration of experimental treatment: Naloxegol 25mg administrated once daily from surgery for up to 7 days
|
Oral administration once daily
Other Names:
|
PLACEBO_COMPARATOR: Placebo
ERAS program with administration of placebo: Placebo administrated once daily from surgery for up to 7 days
|
Oral administration once daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time of hospital discharge
Time Frame: Date at which treatment is initiated and date of hospital discharge (up to 12 days)
|
Comparaison between treatment group and placebo group for post-operative length of stay between the date of hospital discharge and the date of surgery
|
Date at which treatment is initiated and date of hospital discharge (up to 12 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of reinsertion of nasogastric tube
Time Frame: From post-surgery to hospital discharge (up to 12 days)
|
Comparaison between treatment group and placebo group for rate of reinsertion of nasogastric tube
|
From post-surgery to hospital discharge (up to 12 days)
|
Time to reach gastrointestinal recovery
Time Frame: Date at which the patient has the first gaz from post-surgery (up to 12 days)
|
Comparaison between treatment group and placebo group for time ot reach gastrointestinal recovery
|
Date at which the patient has the first gaz from post-surgery (up to 12 days)
|
Rate of 30-day postoperative complications
Time Frame: Postoperative complications from surgery, to 30-day postsurgery and to 90 postsurgery with Clavien-Dindo classification (up to 3 motnhs)
|
Comparaison between treatment group and placebo group for rate of 30-day postoperative complications with Clavien-Dindo classification grade I-V
|
Postoperative complications from surgery, to 30-day postsurgery and to 90 postsurgery with Clavien-Dindo classification (up to 3 motnhs)
|
Rate of major postoperative complications of 90-day postoperative period
Time Frame: Major postoperative complications from surgery to 90 postsurgery with Clavien-Dindo classification (up to 3 motnhs)
|
Comparaison between treatment group and placebo group for rate of major postoperative complications with Clavien-Dindo classification grade III-IV-V
|
Major postoperative complications from surgery to 90 postsurgery with Clavien-Dindo classification (up to 3 motnhs)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Géraldine Pignot, MD, PhD, Isntitut Paoli-Calmettes
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ANTAGOCYST-01-IPC 2019-034
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage III Bladder Cancer | No Evidence of Disease | Stage II Bladder Cancer | Stage IVA Bladder Cancer | Stage IVB Bladder CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedMuscle-Invasive Bladder Carcinoma | Bladder Cancer Stage II | Bladder Cancer Stage III | Bladder Cancer Stage IVUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Cancer | Urinary Complications | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer
-
Fox Chase Cancer CenterTerminatedStage III Bladder Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Squamous Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer | Stage II Bladder CancerUnited States
-
National Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
National Cancer Institute (NCI)TerminatedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Bladder Urothelial Carcinoma | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Stage II Bladder CancerUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Bristol-Myers SquibbRecruitingUrinary Bladder Cancer | Invasive Bladder CancerNetherlands
-
Taris Biomedical LLCBristol-Myers SquibbTerminatedBladder Cancer TNM Staging Primary Tumor (T) T2 | Bladder Cancer TNM Staging Primary Tumor (T) T2A | Bladder Cancer TNM Staging Primary Tumor (T) T2B | Bladder Cancer TNM Staging Primary Tumor (T) T3 | Bladder Cancer TNM Staging Primary Tumor (T) T3A | Bladder Cancer TNM Staging Primary Tumor... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8United States
Clinical Trials on Naloxégol oxalate
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National... and other collaboratorsCompletedHyperoxaluria | Enteric HyperoxaluriaUnited States
-
Federal University of UberlandiaCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Fundação de Amparo...UnknownDentin Sensitivity | Dentin Hypersensitivity | Dentine Hypersensitivity | Hypersensitivity DentinBrazil
-
University of MinnesotaCompletedTooth SensitivityUnited States
-
Procter and GambleCompletedDentin SensitivityUnited States
-
University of Alabama at BirminghamNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University...RecruitingHealthy | Kidney Calculi | Nephrolithiasis | Urolithiasis | Kidney Stone | Nephrolithiasis, Calcium Oxalate | Oxaluria | Urolithiasis, Calcium Oxalate | Oxalate UrolithiasisUnited States
-
Procter and GambleCompletedDentin SensitivityUnited States
-
Allena PharmaceuticalsCompletedNephrolithiasis | HyperoxaluriaUnited States
-
Allena PharmaceuticalsCompletedEnteric Hyperoxaluria | Primary Hyperoxaluria | HyperoxalemiaUnited States, United Kingdom, Germany
-
University of Alabama at BirminghamNational Institutes of Health (NIH)Recruiting